+Compare
PLX
Stock ticker:
ASE
AS OF
Jul 1 closing price
Price
$1.08
Change
-$0.00 (-0.00%)
Capitalization
51.06M

PLX Price Prediction, Protalix BioTherapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jul 01, 2022

PLX sees its Stochastic Oscillator ascending out of oversold territory

On June 23, 2022, the Stochastic Oscillator for PLX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 77 instances where the indicator left the oversold zone. In 68 of the 77 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 29, 2022. You may want to consider a long position or call options on PLX as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PLX advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 118 cases where PLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PLX turned negative on June 13, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

PLX moved below its 50-day moving average on June 06, 2022 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PLX broke above its upper Bollinger Band on May 31, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (227.273) is normal, around the industry mean (24.469). P/E Ratio (0.000) is within average values for comparable stocks, (93.841). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.919). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (1.148) is also within normal values, averaging (306.529).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

PLX is expected to report earnings to -5 cents per share on August 11

Protalix BioTherapeutics PLX Stock Earnings Reports
Q2'22
Est.
$-0.05
Q1'22
Missed
by $0.01
Q4'21
Missed
by $0.03
Q3'21
Beat
by $0.03
Q2'21
Missed
by $0.17
The last earnings report on May 16 showed earnings per share of -5 cents, missing the estimate of -3 cents. With 17.33K shares outstanding, the current market capitalization sits at 51.06M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.73B. The market cap for tickers in the group ranges from 2.5K to 250.34B. NONOF holds the highest valuation in this group at 250.34B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -36%. EVFM experienced the highest price growth at 145%, while PCNTD experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -54%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -18 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of recombinant therapeutic proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Servicestothe Health Industry
Address
2 University Plaza
Phone
+1 201 696-9345
Employees
206
Web
https://www.protalix.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AENZ1.270.07
+5.83%
Aenza SAA
MOMO5.300.25
+4.95%
Hello Group
PECO33.990.58
+1.74%
Phillips Edison & Company
LTBR4.700.04
+0.86%
Lightbridge Corp
KLAC296.26-22.82
-7.15%
KLA Corp

PLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PLX has been loosely correlated with ENLV. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then ENLV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
-0.46%
ENLV - PLX
36%
Loosely correlated
-1.33%
MBRX - PLX
36%
Loosely correlated
+1.38%
VTGN - PLX
35%
Loosely correlated
-0.90%
ACHV - PLX
34%
Loosely correlated
+0.61%
AUTL - PLX
34%
Loosely correlated
-2.83%
More